Background Alzheimer's disease (AD) is the leading cause of dementia affecting greater
than 26 million people worldwide. Although cerebrospinal fluid (CSF) levels of Aβ 42, tau …

Patients with Alzheimer's disease (AD) and Parkinson's disease (PD) often have overlap in
clinical presentation and brain neuropathology suggesting that these two diseases share …

Proteomics involves the identification of unknown proteins following their separation, often
using two‐dimensional electrophoresis, digestion of particular proteins of interest by trypsin …

Ante-mortem diagnosis of neurodegenerative disorders based on clinical features alone is
associated with variable sensitivity and specificity, and biomarkers can potentially improve …

Parkinson's disease (PD) is an age-related, threatening neurodegenerative disorder with no
reliable treatment till date. Identification of specific and reliable biomarker is a major …

Proteomics technologies have been widely used in the investigation of neurodegenerative
and psychiatric disorders, and in particular in the detection of differences between healthy …

This special issue of Progress in Neurobiology entitled “Biomarkers for Neurodegenerative
Disorders” is a biomarker tour de force as a result of the heroic efforts of the experts in …

This review addresses the challenges of neuroproteomics and recent progress in
biomarkers and tests for neurodegenerative diseases, including Alzheimer's disease …

Introduction We sought to determine if our previously validated proteomic profile for
detecting Alzheimer's disease would detect Parkinson's disease (PD) and distinguish PD …

The diagnosis of neurodegenerative diseases within neurology and psychiatry are
hampered by the difficulty in getting biopsies and thereby validating the diagnosis by …